Advertisement

ASH Honors Ross L. Levine, MD, With 2018 William Dameshek Prize


Advertisement
Get Permission

Ross L. Levine, MD

Ross L. Levine, MD

The American Society of Hematology (ASH) will present the 2018 William Dameshek Prize to Ross L. Levine, MD, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, for his discoveries in the field of leukemia and myeloproliferative neoplasms during the 2018 ASH Annual Meeting & Exposition in San Diego.

“There has never been a better time to be in the hematology field. As a physician scientist, I try to remember to always follow the questions that challenge me and ensure that I have a great team by my side throughout my career,” said Dr. Levine. “It is a tremendous honor to be recognized by the professional society that has supported my career, and I am delighted to accept this award on behalf of all my trainees, collaborators, and mentors.”

The William Dameshek Prize is awarded to an early- or mid-career hematologist who has made a recent outstanding contribution to the field of hematology. This prize is named after the late William Dameshek, MD, a past president of ASH and the original editor of Blood

Leader in Hematology

Dr. Levine is the Laurence Joseph Dineen Chair in Leukemia Research at Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill Cornell Medical College in New York City. He is a recognized leader in the study of leukemia, and his work in epigenetics in the development of this hematologic malignancy, which has initiated a paradigm shift from identification of genetic mutations to the consideration of how other variants contribute to blood cancer. Dr. Levine was one of the first investigators to define the role of TET2, IDH1, and IDH2 mutations in hematologic malignancies, which has led to the development of molecularly targeted therapies for acute myeloid leukemia. Dr. Levine also played a key role in deciphering the role of JAK-STAT activation in myeloproliferative neoplasms, which has led to approved therapies for patients with myeloproliferative neoplasms. ■


Advertisement

Advertisement



Advertisement